Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Excitement is building as #FFN2021 is kicking-off next week! At UCB we are committed to finding innovative scientific solutions to improve patient outcomes. Register now to learn more about the cutting-edge research in #fracture care and the bone field:
— UCB News (@ucb_news) 24.09.2021 -
Rare Disease Connect in #Neurology 2021, the inaugural event in our educational series for neuromuscular experts who are striving to improve the lives of those living with #MyastheniaGravis, is open for registrations! Find out more via the link below http
— UCB News (@ucb_news) 23.09.2021 -
A tailored game plan starts with knowledge - click here to take the #AdvantageHers chronic inflammatory disease questionnaire and download helpful resources today! https://t.co/lTCXHtX4kv
— UCB News (@ucb_news) 22.09.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
